ImmunOs Therapeutics AG focuses on the development of a new class of biologics for the treatment of cancer, autoimmune and infectious diseases. The Company has established a versatile, proprietary R&D platform for the development of HLA-based therapeutics addressing multiple targets via a single protein.
Its novel compounds are fully human and modulate both the innate and adaptive immune system. By contrast, currently available immunotherapeutics focus on the activation of T cells / T lymphocytes in the adaptive immune system only.
ImmunOs Therapeutics´ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses.
These LILRB receptors are expressed on many tumors and play a significant role in the suppression of the immune system, including macrophages, MDSCs, T cells, and NK cells.
ImmunOs Therapeutics AG has raised financing from top-tier investors such as Pfizer Ventures, BioMed Partners, Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd and undisclosed private investors.
The Company is a spin-off from the Universities of Zurich and Basel and based in Schlieren, Switzerland.